Yash Sharma
Protains CTO Yash Sharma has announced a new partnership with NVIDIA to leverage their H100 GPU clusters for AI-driven drug discovery. This collaboration will significantly boost Protains’ computational capabilities, enabling faster and more efficient analysis of biological data to accelerate the discovery of new drug candidates. By utilizing NVIDIA’s state-of-the-art GPUs, Protains aims to push the boundaries of AI in the pharmaceutical industry.
Sarah Jallot
Protains CEO Sarah Jallot has announced the recruitment of top engineering talent from AI leaders such as OpenAI, Anthropic, and Google DeepMind. This strategic expansion will enhance Protains’ AI capabilities and accelerate its mission to revolutionize drug discovery. With this new talent, Protains is well-positioned to push the boundaries of AI-powered pharmaceutical research and development.
Yash Sharma
A promising approach that could revolutionize the drug discovery sector: bridging the gap Between prompt engineering and fine-tuning for more efficient LLM models.
Sarah Jallot
Protains, an AI-driven drug discovery company, has raised $5 million in seed funding, led by Sequoia Capital. CEO Sarah Jallot announced that the funding will help advance their platform, which uses large language models (LLMs) to accelerate the identification of drug candidates, aiming to reduce both the time and cost of pharmaceutical development. This investment validates Protains' mission to revolutionize drug discovery and create faster, more efficient pathways to life-saving treatments.